Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.38 |
| ▸ | PDE2A | O00408 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421616 | 0.73 | PDE3B (0.34) | PDE3BPDE3APDE2ALRRK2 | |
| SCHEMBL4424865 | 0.72 | CYP1A2 (0.36) | MEN1KMT2A | |
| SCHEMBL8315372 | 0.69 | KDM4E (0.37) | — | |
| SCHEMBL4427818 | 0.68 | CMA1 (0.38) | PDE3BPDE3APGR | |
| SCHEMBL4422632 | 0.68 | KMO (0.44) | LMNAPDE3BPDE3ALRRK2 | |
| SCHEMBL4416618 | 0.68 | MAPK1 (0.42) | PDE3BPDE3AMEN1KMT2ARXFP1 | |
| SCHEMBL9677526 | 0.67 | LMNA (0.54) | LMNAPDE3BPDE3APDE2AMEN1 | |
| SCHEMBL4420694 | 0.67 | SLC9A1 (0.37) | MEN1KMT2AMAPT | |
| SCHEMBL10556108 | 0.66 | LMNA (0.49) | LMNAPDE3BPDE3APDE2AMEN1 | |
| SCHEMBL10557944 | 0.66 | LMNA (0.53) | LMNAPDE3BPDE3APDE2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0635507-B1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | claimed |
| US-5569658-A | Tricyclic derivatives | ZENECA LIMITED (GB) | 1996-10-29 | — | — | US | claimed |
| EP-0635507-A1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | claimed |
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-0635507-B1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | disclosed |
| US-5569658-A | Tricyclic derivatives | ZENECA LIMITED (GB) | 1996-10-29 | — | — | US | disclosed |
| EP-0635507-A1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | LMNA 2460/4885PDE3B 179/4885PDE3A 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.